Cargando…

A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings

Using a patient’s genetic information to inform medication prescriptions can be clinically effective; however, the practice has not been widely implemented. Health systems need guidance on how to engage with providers to improve pharmacogenetic test utilization. Approaches from the field of implemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sperber, Nina R., Cragun, Deborah, Roberts, Megan C., Bendz, Lisa M., Ince, Parker, Gonzales, Sarah, Haga, Susanne B., Wu, R. Ryanne, Petry, Natasha J., Ramsey, Laura, Uber, Ryley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410119/
https://www.ncbi.nlm.nih.gov/pubmed/36013262
http://dx.doi.org/10.3390/jpm12081313
_version_ 1784775016934539264
author Sperber, Nina R.
Cragun, Deborah
Roberts, Megan C.
Bendz, Lisa M.
Ince, Parker
Gonzales, Sarah
Haga, Susanne B.
Wu, R. Ryanne
Petry, Natasha J.
Ramsey, Laura
Uber, Ryley
author_facet Sperber, Nina R.
Cragun, Deborah
Roberts, Megan C.
Bendz, Lisa M.
Ince, Parker
Gonzales, Sarah
Haga, Susanne B.
Wu, R. Ryanne
Petry, Natasha J.
Ramsey, Laura
Uber, Ryley
author_sort Sperber, Nina R.
collection PubMed
description Using a patient’s genetic information to inform medication prescriptions can be clinically effective; however, the practice has not been widely implemented. Health systems need guidance on how to engage with providers to improve pharmacogenetic test utilization. Approaches from the field of implementation science may shed light on the complex factors affecting pharmacogenetic test use in real-world settings and areas to target to improve utilization. This paper presents an approach to studying the application of precision medicine that utilizes mixed qualitative and quantitative methods and implementation science frameworks to understand which factors or combinations consistently account for high versus low utilization of pharmocogenetic testing. This approach involves two phases: (1) collection of qualitative and quantitative data from providers—the cases—at four clinical institutions about their experiences with, and utilization of, pharmacogenetic testing to identify salient factors; and (2) analysis using a Configurational Comparative Method (CCM), using a mathematical algorithm to identify the minimally necessary and sufficient factors that distinguish providers who have higher utilization from those with low utilization. Advantages of this approach are that it can be used for small to moderate sample sizes, and it accounts for conditions found in real-world settings by demonstrating how they coincide to affect utilization.
format Online
Article
Text
id pubmed-9410119
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94101192022-08-26 A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings Sperber, Nina R. Cragun, Deborah Roberts, Megan C. Bendz, Lisa M. Ince, Parker Gonzales, Sarah Haga, Susanne B. Wu, R. Ryanne Petry, Natasha J. Ramsey, Laura Uber, Ryley J Pers Med Article Using a patient’s genetic information to inform medication prescriptions can be clinically effective; however, the practice has not been widely implemented. Health systems need guidance on how to engage with providers to improve pharmacogenetic test utilization. Approaches from the field of implementation science may shed light on the complex factors affecting pharmacogenetic test use in real-world settings and areas to target to improve utilization. This paper presents an approach to studying the application of precision medicine that utilizes mixed qualitative and quantitative methods and implementation science frameworks to understand which factors or combinations consistently account for high versus low utilization of pharmocogenetic testing. This approach involves two phases: (1) collection of qualitative and quantitative data from providers—the cases—at four clinical institutions about their experiences with, and utilization of, pharmacogenetic testing to identify salient factors; and (2) analysis using a Configurational Comparative Method (CCM), using a mathematical algorithm to identify the minimally necessary and sufficient factors that distinguish providers who have higher utilization from those with low utilization. Advantages of this approach are that it can be used for small to moderate sample sizes, and it accounts for conditions found in real-world settings by demonstrating how they coincide to affect utilization. MDPI 2022-08-13 /pmc/articles/PMC9410119/ /pubmed/36013262 http://dx.doi.org/10.3390/jpm12081313 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sperber, Nina R.
Cragun, Deborah
Roberts, Megan C.
Bendz, Lisa M.
Ince, Parker
Gonzales, Sarah
Haga, Susanne B.
Wu, R. Ryanne
Petry, Natasha J.
Ramsey, Laura
Uber, Ryley
A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings
title A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings
title_full A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings
title_fullStr A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings
title_full_unstemmed A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings
title_short A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings
title_sort mixed-methods protocol to identify best practices for implementing pharmacogenetic testing in clinical settings
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410119/
https://www.ncbi.nlm.nih.gov/pubmed/36013262
http://dx.doi.org/10.3390/jpm12081313
work_keys_str_mv AT sperberninar amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT cragundeborah amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT robertsmeganc amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT bendzlisam amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT inceparker amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT gonzalessarah amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT hagasusanneb amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT wurryanne amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT petrynatashaj amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT ramseylaura amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT uberryley amixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT sperberninar mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT cragundeborah mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT robertsmeganc mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT bendzlisam mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT inceparker mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT gonzalessarah mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT hagasusanneb mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT wurryanne mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT petrynatashaj mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT ramseylaura mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings
AT uberryley mixedmethodsprotocoltoidentifybestpracticesforimplementingpharmacogenetictestinginclinicalsettings